NYSE:WAT - Waters Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $251.25
  • Forecasted Upside: -26.63 %
  • Number of Analysts: 11
  • Breakdown:
  • 3 Sell Ratings
  • 7 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$342.44
▼ -0.27 (-0.08%)

This chart shows the closing price for WAT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Waters Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WAT

Analyst Price Target is $251.25
▼ -26.63% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Waters in the last 3 months. The average price target is $251.25, with a high forecast of $300.00 and a low forecast of $185.00. The average price target represents a -26.63% upside from the last price of $342.44.

This chart shows the closing price for WAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 polled investment analysts is to hold stock in Waters. This rating has held steady since July 2020, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 4 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 6 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 5 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 5 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 5 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 5 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 3 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 3 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021SVB LeerinkBoost Price TargetMarket Perform$290.00 ➝ $300.00Low
5/6/2021Wells Fargo & CompanyBoost Price TargetUnderweight$280.00 ➝ $290.00Low
2/3/2021CitigroupBoost Price Target$250.00 ➝ $300.00Low
1/7/2021Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$235.00N/A
12/17/2020Cleveland ResearchUpgradeUnderperform ➝ BuyLow
12/16/2020Smith Barney CitigroupUpgradeSell ➝ NeutralLow
12/16/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeSell ➝ Neutral$185.00 ➝ $240.00N/A
12/2/2020The Goldman Sachs GroupInitiated CoverageNeutral$230.00Low
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$235.00Medium
10/28/2020Stifel NicolausBoost Price TargetHold$220.00 ➝ $230.00Medium
10/28/2020Smith Barney CitigroupBoost Price Target$180.00 ➝ $185.00Low
10/28/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$230.00 ➝ $235.00Low
10/28/2020SVB LeerinkBoost Price TargetMarket Perform$225.00 ➝ $230.00Low
7/29/2020Stifel NicolausBoost Price TargetHold$180.00 ➝ $220.00High
7/29/2020SVB LeerinkBoost Price TargetMarket Perform$195.00 ➝ $225.00High
7/29/2020CitigroupBoost Price TargetSell$150.00 ➝ $180.00High
7/28/2020Needham & Company LLCInitiated CoverageSellHigh
7/28/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
7/16/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$175.00 ➝ $225.00Medium
4/29/2020Bank of AmericaLower Price TargetUnderperform$160.00 ➝ $145.00High
4/29/2020Stifel NicolausBoost Price TargetHold$176.00 ➝ $180.00Medium
4/29/2020SVB LeerinkLower Price TargetMarket Perform$210.00 ➝ $195.00High
4/28/2020Needham & Company LLCInitiated CoverageSellHigh
4/28/2020UBS GroupLower Price TargetNeutral$223.00 ➝ $212.00Low
4/2/2020Stifel NicolausLower Price TargetHold$210.00 ➝ $176.00Low
3/30/2020Wells Fargo & CompanyLower Price TargetUnderweight$210.00 ➝ $180.00Medium
3/26/2020BarclaysLower Price TargetUnderweight$186.00 ➝ $172.00High
3/20/2020CitigroupLower Price TargetSell$190.00 ➝ $150.00Medium
2/4/2020Needham & Company LLCReiterated RatingSellHigh
1/8/2020Needham & Company LLCDowngradeHold ➝ UnderperformMedium
1/7/2020Wells Fargo & CompanyInitiated CoverageUnderweight$215.00High
1/6/2020CitigroupInitiated CoverageSell$190.00Medium
1/3/2020Needham & Company LLCInitiated CoverageHold$177.00Medium
1/3/2020Bank of AmericaUpgradeUnderperform ➝ NeutralMedium
12/4/2019BTIG ResearchDowngradeBuy ➝ NeutralLow
11/14/2019Stifel NicolausInitiated CoverageHold$210.00Medium
10/29/2019Needham & Company LLCReiterated RatingHoldHigh
10/9/2019BarclaysDowngradeEqual Weight ➝ Underweight$210.00 ➝ $195.00Low
7/16/2019Bank of AmericaDowngradeNeutral ➝ UnderperformLow
6/12/2019Cleveland ResearchDowngradeNeutral ➝ UnderperformMedium
5/30/2019Wolfe ResearchInitiated CoverageUnderperform ➝ UnderperformLow
4/24/2019UBS GroupLower Price TargetNeutral ➝ Neutral$248.00 ➝ $230.00Low
4/24/2019Robert W. BairdLower Price TargetNeutral ➝ Neutral$211.00 ➝ $209.00Low
4/24/2019BarclaysLower Price TargetEqual Weight ➝ Equal Weight$218.00 ➝ $210.00Low
1/25/2019BarclaysReiterated RatingHold$200.00Medium
1/24/2019BTIG ResearchBoost Price TargetBuy$260.00Medium
1/24/2019Robert W. BairdDowngradeOutperform ➝ Neutral$191.00 ➝ $211.00Medium
1/3/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
1/2/2019Needham & Company LLCInitiated CoverageHold ➝ Hold$177.00High
12/12/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$185.00 ➝ $180.00Low
12/9/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$200.83Low
11/30/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$185.00 ➝ $180.00Medium
10/24/2018UBS GroupLower Price TargetNeutral ➝ Neutral$210.00 ➝ $200.00High
10/24/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$200.00 ➝ $190.00High
10/24/2018JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral$200.00 ➝ $185.00High
10/11/2018Cleveland ResearchUpgradeSell ➝ NeutralHigh
10/10/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$204.00 ➝ $211.00Medium
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$210.00Low
10/8/2018SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
7/25/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$201.00 ➝ $212.00Medium
7/25/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$205.00 ➝ $204.00Low
7/17/2018Janney Montgomery ScottDowngradeBuy ➝ Neutral$230.00 ➝ $211.00Medium
7/16/2018Bank of AmericaDowngradeNeutral ➝ Underperform$190.00Medium
7/13/2018Morgan StanleyBoost Price TargetEqual Weight$200.00 ➝ $205.00High
6/14/2018Cleveland ResearchDowngradeNeutral ➝ UnderperformMedium
4/25/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$208.00 ➝ $200.00Medium
4/25/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$218.00 ➝ $200.00Low
4/25/2018Robert W. BairdLower Price TargetOutperform ➝ Outperform$220.00 ➝ $201.00Low
4/25/2018Jefferies Financial GroupReiterated RatingHold$200.00Medium
4/25/2018SVB LeerinkSet Price TargetBuy$230.00 ➝ $214.00Medium
4/25/2018CowenReiterated RatingHold$215.00Medium
4/11/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$237.00 ➝ $218.00Low
1/25/2018BTIG ResearchReiterated RatingBuyLow
1/24/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$202.00 ➝ $208.00N/A
1/24/2018Janney Montgomery ScottBoost Price TargetBuy ➝ Buy$200.00 ➝ $230.00N/A
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$180.00 ➝ $200.00N/A
1/24/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$219.00 ➝ $220.00N/A
1/24/2018CitigroupBoost Price TargetNeutral ➝ Neutral$190.00 ➝ $223.00N/A
1/23/2018William BlairReiterated RatingOutperformLow
1/8/2018BarclaysReiterated RatingHold$202.00Medium
1/5/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$230.00Medium
1/3/2018Evercore ISIInitiated CoverageIn-Line$198.00Medium
12/4/2017Morgan StanleyUpgradeUnderweight ➝ Equal Weight$192.00High
11/10/2017Bank of AmericaBoost Price TargetNeutral$192.00 ➝ $202.00N/A
11/3/2017CowenReiterated RatingHold$190.00N/A
10/25/2017CitigroupReiterated RatingNeutral$180.00N/A
10/25/2017BarclaysBoost Price TargetEqual Weight$188.00 ➝ $193.00N/A
10/25/2017Deutsche Bank AktiengesellschaftBoost Price TargetHold$199.00 ➝ $200.00N/A
10/25/2017Robert W. BairdBoost Price TargetOutperform$196.00 ➝ $199.00N/A
10/9/2017Cleveland ResearchDowngradeBuy ➝ NeutralN/A
10/6/2017Morgan StanleyReiterated RatingUnderweight ➝ Underweight$183.00 ➝ $192.00N/A
9/26/2017The Goldman Sachs GroupInitiated CoverageHold$180.00Low
8/31/2017Jefferies Financial GroupReiterated RatingHold$175.00Low
7/27/2017Jefferies Financial GroupReiterated RatingHold$175.00Low
7/26/2017Morgan StanleyReiterated RatingUnderweight$174.00 ➝ $183.00Low
7/21/2017Bank of AmericaReiterated RatingNeutral$180.00 ➝ $192.00Low
7/14/2017CowenReiterated RatingHold$190.00Medium
7/14/2017Jefferies Financial GroupReiterated RatingHold$170.00Low
7/13/2017Wells Fargo & CompanyReiterated RatingOutperform$195.00 ➝ $205.00Low
7/10/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$183.00 ➝ $194.00High
5/1/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$185.00 ➝ $200.00Medium
4/29/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$166.00 ➝ $183.00Medium
4/26/2017BarclaysSet Price TargetHold$160.00Low
4/26/2017CowenBoost Price TargetMarket Perform$160.00 ➝ $175.00Low
4/25/2017Cantor FitzgeraldReiterated RatingBuy$170.00 ➝ $190.00Low
3/3/2017Evercore ISIDowngradeHold ➝ UnderperformN/A
3/3/2017Jefferies Financial GroupBoost Price TargetHold$147.00 ➝ $150.00N/A
3/3/2017Cantor FitzgeraldReiterated RatingOverweight$170.00N/A
1/24/2017Cantor FitzgeraldSet Price TargetBuy$170.00N/A
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$160.00N/A
1/9/2017BarclaysReiterated RatingHold$148.00N/A
1/6/2017William BlairUpgradeMarket Perform ➝ OutperformN/A
12/8/2016Cantor FitzgeraldSet Price TargetBuy$170.00N/A
11/10/2016SVB LeerinkReiterated RatingOutperform$163.00N/A
10/28/2016Jefferies Financial GroupReiterated RatingHold$150.00 ➝ $145.00N/A
10/25/2016Cantor FitzgeraldReiterated RatingBuy$170.00N/A
7/27/2016CitigroupBoost Price TargetNeutral$138.00 ➝ $160.00N/A
7/27/2016BarclaysBoost Price TargetEqual Weight$130.00 ➝ $157.00N/A
7/27/2016Jefferies Financial GroupBoost Price TargetHold$128.00 ➝ $150.00N/A
7/27/2016MizuhoBoost Price TargetNeutral$130.00 ➝ $145.00N/A
7/26/2016Evercore ISIBoost Price TargetHold$140.50 ➝ $154.00N/A
7/26/2016Cantor FitzgeraldBoost Price TargetBuy$163.00 ➝ $173.00N/A
(Data available from 6/21/2016 forward)
Waters logo
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Read More

Today's Range

Now: $342.44
Low: $341.09
High: $345.90

50 Day Range

MA: $314.40
Low: $296.27
High: $346.56

52 Week Range

Now: $342.44
Low: $171.38
High: $348.10

Volume

484,459 shs

Average Volume

388,471 shs

Market Capitalization

$21.13 billion

P/E Ratio

34.70

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Waters?

The following Wall Street sell-side analysts have issued stock ratings on Waters in the last twelve months: Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cleveland Research, JPMorgan Chase & Co., KeyCorp, Needham & Company LLC, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for WAT.

What is the current price target for Waters?

8 Wall Street analysts have set twelve-month price targets for Waters in the last year. Their average twelve-month price target is $251.25, suggesting a possible downside of 26.7%. SVB Leerink LLC has the highest price target set, predicting WAT will reach $300.00 in the next twelve months. Smith Barney Citigroup has the lowest price target set, forecasting a price of $185.00 for Waters in the next year.
View the latest price targets for WAT.

What is the current consensus analyst rating for Waters?

Waters currently has 3 sell ratings, 7 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in WAT, but not buy more shares or sell existing shares.
View the latest ratings for WAT.

What other companies compete with Waters?

How do I contact Waters' investor relations team?

Waters' physical mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier's listed phone number is 508-478-2000 and its investor relations email address is [email protected] The official website for Waters is www.waters.com.